Gastrointestinal stromal tumours: Consensus statement on diagnosis and treatment

Martin E. Blackstein, Jean Yves Blay, Christopher Corless, David K. Driman, Robert Riddell, Denis Soulières, Carol J. Swallow, Shailendra Verma, Louis R. Bégin, Pierre Dubé, Alvarado Figueredo, Massom Haider, Korosh Khalili, Margaret Knowling, Calvin Law, Bernard L'Espérance, Donald Morris, Karen Mulder, David Owen, Aaron PollettStewart Rorke, Ralph Wong, Jawaid Younus

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

In the multidisciplinary management of gastrointestinal stromal tumours (GISTs), there is a need to coordinate the efforts of pathology, radiology, surgery and oncology. Surgery is the mainstay for resectable nonmetastatic GISTs, but virtually all GISTs are associated with a risk of metastasis. Imatinib 400 mg/day with or without surgery is the recommended first-line treatment for recurrent or metastatic GIST; a higher dose may be considered in patients who progress, develop secondary resistance or present with specific genotypic characteristics. Adjuvant or neoadjuvant imatinib is not advised for resectable non-metastatic GISTs. Neoadjuvant imatinib may be considered when surgery would result in significant morbidity or loss of organ function. Follow-up computed tomography imaging is recommended every three to six months for at least five years. Patients with metastatic disease should be continued on imatinib due to the high risk of recurrence on discontinuation of therapy. Treatment should be continued until there is progression or intolerable adverse effects. If dose escalation with imatinib fails, a clinical trial with novel agents alone or in combination may be considered. The present recommendations were developed at a surgical subcommittee meeting and a subsequent full Advisory Committee meeting held in Toronto, Ontario, in April 2005, under the sponsorship of Novartis Pharmaceuticals Canada Inc.

Original languageEnglish (US)
Pages (from-to)157-163
Number of pages7
JournalCanadian Journal of Gastroenterology
Volume20
Issue number3
StatePublished - Mar 2006

Fingerprint

Gastrointestinal Stromal Tumors
Therapeutics
Ontario
Advisory Committees
Radiology
Canada
Tomography
Imatinib Mesylate
Clinical Trials
Pathology
Neoplasm Metastasis
Morbidity
Recurrence
Pharmaceutical Preparations

Keywords

  • Consensus
  • Gastrointestinal stromal tumour
  • Imatinib
  • Oncology
  • Treatment

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Blackstein, M. E., Blay, J. Y., Corless, C., Driman, D. K., Riddell, R., Soulières, D., ... Younus, J. (2006). Gastrointestinal stromal tumours: Consensus statement on diagnosis and treatment. Canadian Journal of Gastroenterology, 20(3), 157-163.

Gastrointestinal stromal tumours : Consensus statement on diagnosis and treatment. / Blackstein, Martin E.; Blay, Jean Yves; Corless, Christopher; Driman, David K.; Riddell, Robert; Soulières, Denis; Swallow, Carol J.; Verma, Shailendra; Bégin, Louis R.; Dubé, Pierre; Figueredo, Alvarado; Haider, Massom; Khalili, Korosh; Knowling, Margaret; Law, Calvin; L'Espérance, Bernard; Morris, Donald; Mulder, Karen; Owen, David; Pollett, Aaron; Rorke, Stewart; Wong, Ralph; Younus, Jawaid.

In: Canadian Journal of Gastroenterology, Vol. 20, No. 3, 03.2006, p. 157-163.

Research output: Contribution to journalArticle

Blackstein, ME, Blay, JY, Corless, C, Driman, DK, Riddell, R, Soulières, D, Swallow, CJ, Verma, S, Bégin, LR, Dubé, P, Figueredo, A, Haider, M, Khalili, K, Knowling, M, Law, C, L'Espérance, B, Morris, D, Mulder, K, Owen, D, Pollett, A, Rorke, S, Wong, R & Younus, J 2006, 'Gastrointestinal stromal tumours: Consensus statement on diagnosis and treatment', Canadian Journal of Gastroenterology, vol. 20, no. 3, pp. 157-163.
Blackstein ME, Blay JY, Corless C, Driman DK, Riddell R, Soulières D et al. Gastrointestinal stromal tumours: Consensus statement on diagnosis and treatment. Canadian Journal of Gastroenterology. 2006 Mar;20(3):157-163.
Blackstein, Martin E. ; Blay, Jean Yves ; Corless, Christopher ; Driman, David K. ; Riddell, Robert ; Soulières, Denis ; Swallow, Carol J. ; Verma, Shailendra ; Bégin, Louis R. ; Dubé, Pierre ; Figueredo, Alvarado ; Haider, Massom ; Khalili, Korosh ; Knowling, Margaret ; Law, Calvin ; L'Espérance, Bernard ; Morris, Donald ; Mulder, Karen ; Owen, David ; Pollett, Aaron ; Rorke, Stewart ; Wong, Ralph ; Younus, Jawaid. / Gastrointestinal stromal tumours : Consensus statement on diagnosis and treatment. In: Canadian Journal of Gastroenterology. 2006 ; Vol. 20, No. 3. pp. 157-163.
@article{ff88a216518d4480ac47de6b46988afd,
title = "Gastrointestinal stromal tumours: Consensus statement on diagnosis and treatment",
abstract = "In the multidisciplinary management of gastrointestinal stromal tumours (GISTs), there is a need to coordinate the efforts of pathology, radiology, surgery and oncology. Surgery is the mainstay for resectable nonmetastatic GISTs, but virtually all GISTs are associated with a risk of metastasis. Imatinib 400 mg/day with or without surgery is the recommended first-line treatment for recurrent or metastatic GIST; a higher dose may be considered in patients who progress, develop secondary resistance or present with specific genotypic characteristics. Adjuvant or neoadjuvant imatinib is not advised for resectable non-metastatic GISTs. Neoadjuvant imatinib may be considered when surgery would result in significant morbidity or loss of organ function. Follow-up computed tomography imaging is recommended every three to six months for at least five years. Patients with metastatic disease should be continued on imatinib due to the high risk of recurrence on discontinuation of therapy. Treatment should be continued until there is progression or intolerable adverse effects. If dose escalation with imatinib fails, a clinical trial with novel agents alone or in combination may be considered. The present recommendations were developed at a surgical subcommittee meeting and a subsequent full Advisory Committee meeting held in Toronto, Ontario, in April 2005, under the sponsorship of Novartis Pharmaceuticals Canada Inc.",
keywords = "Consensus, Gastrointestinal stromal tumour, Imatinib, Oncology, Treatment",
author = "Blackstein, {Martin E.} and Blay, {Jean Yves} and Christopher Corless and Driman, {David K.} and Robert Riddell and Denis Souli{\`e}res and Swallow, {Carol J.} and Shailendra Verma and B{\'e}gin, {Louis R.} and Pierre Dub{\'e} and Alvarado Figueredo and Massom Haider and Korosh Khalili and Margaret Knowling and Calvin Law and Bernard L'Esp{\'e}rance and Donald Morris and Karen Mulder and David Owen and Aaron Pollett and Stewart Rorke and Ralph Wong and Jawaid Younus",
year = "2006",
month = "3",
language = "English (US)",
volume = "20",
pages = "157--163",
journal = "Canadian Journal of Gastroenterology and Hepatology",
issn = "2291-2789",
publisher = "Pulsus Group Inc.",
number = "3",

}

TY - JOUR

T1 - Gastrointestinal stromal tumours

T2 - Consensus statement on diagnosis and treatment

AU - Blackstein, Martin E.

AU - Blay, Jean Yves

AU - Corless, Christopher

AU - Driman, David K.

AU - Riddell, Robert

AU - Soulières, Denis

AU - Swallow, Carol J.

AU - Verma, Shailendra

AU - Bégin, Louis R.

AU - Dubé, Pierre

AU - Figueredo, Alvarado

AU - Haider, Massom

AU - Khalili, Korosh

AU - Knowling, Margaret

AU - Law, Calvin

AU - L'Espérance, Bernard

AU - Morris, Donald

AU - Mulder, Karen

AU - Owen, David

AU - Pollett, Aaron

AU - Rorke, Stewart

AU - Wong, Ralph

AU - Younus, Jawaid

PY - 2006/3

Y1 - 2006/3

N2 - In the multidisciplinary management of gastrointestinal stromal tumours (GISTs), there is a need to coordinate the efforts of pathology, radiology, surgery and oncology. Surgery is the mainstay for resectable nonmetastatic GISTs, but virtually all GISTs are associated with a risk of metastasis. Imatinib 400 mg/day with or without surgery is the recommended first-line treatment for recurrent or metastatic GIST; a higher dose may be considered in patients who progress, develop secondary resistance or present with specific genotypic characteristics. Adjuvant or neoadjuvant imatinib is not advised for resectable non-metastatic GISTs. Neoadjuvant imatinib may be considered when surgery would result in significant morbidity or loss of organ function. Follow-up computed tomography imaging is recommended every three to six months for at least five years. Patients with metastatic disease should be continued on imatinib due to the high risk of recurrence on discontinuation of therapy. Treatment should be continued until there is progression or intolerable adverse effects. If dose escalation with imatinib fails, a clinical trial with novel agents alone or in combination may be considered. The present recommendations were developed at a surgical subcommittee meeting and a subsequent full Advisory Committee meeting held in Toronto, Ontario, in April 2005, under the sponsorship of Novartis Pharmaceuticals Canada Inc.

AB - In the multidisciplinary management of gastrointestinal stromal tumours (GISTs), there is a need to coordinate the efforts of pathology, radiology, surgery and oncology. Surgery is the mainstay for resectable nonmetastatic GISTs, but virtually all GISTs are associated with a risk of metastasis. Imatinib 400 mg/day with or without surgery is the recommended first-line treatment for recurrent or metastatic GIST; a higher dose may be considered in patients who progress, develop secondary resistance or present with specific genotypic characteristics. Adjuvant or neoadjuvant imatinib is not advised for resectable non-metastatic GISTs. Neoadjuvant imatinib may be considered when surgery would result in significant morbidity or loss of organ function. Follow-up computed tomography imaging is recommended every three to six months for at least five years. Patients with metastatic disease should be continued on imatinib due to the high risk of recurrence on discontinuation of therapy. Treatment should be continued until there is progression or intolerable adverse effects. If dose escalation with imatinib fails, a clinical trial with novel agents alone or in combination may be considered. The present recommendations were developed at a surgical subcommittee meeting and a subsequent full Advisory Committee meeting held in Toronto, Ontario, in April 2005, under the sponsorship of Novartis Pharmaceuticals Canada Inc.

KW - Consensus

KW - Gastrointestinal stromal tumour

KW - Imatinib

KW - Oncology

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=33645926705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645926705&partnerID=8YFLogxK

M3 - Article

C2 - 16550259

AN - SCOPUS:33645926705

VL - 20

SP - 157

EP - 163

JO - Canadian Journal of Gastroenterology and Hepatology

JF - Canadian Journal of Gastroenterology and Hepatology

SN - 2291-2789

IS - 3

ER -